Eksborg S, Nilsson B
Karolinska Pharmacy, Stockholm, Sweden.
J Chromatogr. 1989 Mar 24;488(2):427-34. doi: 10.1016/s0378-4347(00)82966-7.
A method is given for the determination of idarubicin and its main metabolite, idarubicinol, in plasma from cancer patients. Idarubicin and idarubicinol are extracted from 2-ml samples of buffered plasma (pH 8.1) using chloroform-1-heptanol (9:1). After reextraction into phosphoric acid (0.1 M), separation is performed by reversed-phase liquid chromatography on a LiChrosorb RP-2 column (5 microns) with a mobile phase of acetonitrile-water, acidified with phosphoric acid. The absolute recovery in the range 5-100 ng/ml was greater than 83% with a precision better than 8% (relative standard deviation), using photometric detection at 484 nm. Proper handling of whole blood samples containing idarubidin is essential to avoid metabolic conversion into idarubicinol. Prolonged storage of the drug and its main metabolite under alkaline conditions should be avoided to prevent chemical degradation.
给出了一种测定癌症患者血浆中伊达比星及其主要代谢产物伊达比星醇的方法。伊达比星和伊达比星醇从2毫升缓冲血浆（pH 8.1）样品中用氯仿 - 1 - 庚醇（9:1）萃取。再萃取到磷酸（0.1 M）中后，在LiChrosorb RP - 2柱（5微米）上通过反相液相色谱法进行分离，流动相为用磷酸酸化的乙腈 - 水。在5 - 100 ng/ml范围内，绝对回收率大于83%，精密度优于8%（相对标准偏差），采用484 nm处的光度检测。妥善处理含有伊达比星的全血样品对于避免代谢转化为伊达比星醇至关重要。应避免药物及其主要代谢产物在碱性条件下长时间储存以防止化学降解。
Zotero 插件